If you’ve read three articles on this topic, you’ve probably noticed they all say the same thing. Both medications work. Both are FDA-approved for weight management. Both have side effects. Talk to your doctor.
That’s true. It’s also useless.
If you’re actually trying to decide which one makes sense for your body, you need a clearer framework than “both are good options.” This post walks you through what a clinician thinks about when they’re weighing semaglutide against tirzepatide for a specific patient, and what that means for which one is probably the better fit for you.
The Short Version (For Readers Who Want the Bottom Line)
For most adults pursuing weight management without type 2 diabetes, tirzepatide tends to outperform semaglutide on total weight lost and often produces fewer gastrointestinal side effects at comparable doses. That’s why a lot of metabolic clinics, including ours, lead with tirzepatide.
Semaglutide is still the better choice in specific situations. If you tolerate it well, your insurance covers it, you’ve already started a course, or your weight loss target is modest, semaglutide is doing exactly what it’s supposed to do, and switching for the sake of switching is rarely worth it.
So the real question isn’t “which one wins on average.” It’s “which one fits you.”
What Each Medication Actually Does
Both drugs work on hormones your gut already releases when you eat. They just hit different receptors.
Semaglutide: One Receptor, One Job
Semaglutide is a GLP-1 receptor agonist. It mimics the action of GLP-1, a hormone your gut releases after meals that tells your brain you’re full, slows how fast food leaves your stomach, and helps your pancreas regulate insulin.
Under the brand names Wegovy (FDA-approved for chronic weight management) and Ozempic (FDA-approved for type 2 diabetes), semaglutide has been the go-to GLP-1 medication for years. It works. The data is solid. Most patients lose meaningful weight on it.
Tirzepatide: Two Receptors, Two Jobs
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It does everything semaglutide does, plus it activates GIP, a second gut hormone involved in insulin sensitivity and how your body handles fat after meals.
That second pathway is the reason tirzepatide tends to produce stronger weight loss outcomes. The drug isn’t doing one thing harder. It’s doing two related things at once.
Under the brand names Zepbound (FDA-approved for weight management and obstructive sleep apnea in adults with obesity) and Mounjaro (FDA-approved for type 2 diabetes), tirzepatide has become the standard recommendation in metabolic medicine when the goal is significant fat loss.
How the Two Compare on Weight Loss
Both medications produce weight loss far beyond what diet and exercise alone typically achieve. The difference between them is real, but it’s a matter of degree.
In Eli Lilly’s SURMOUNT-5 trial, a head-to-head comparison of tirzepatide and semaglutide for weight management in non-diabetic adults with obesity, tirzepatide produced greater total weight reduction than semaglutide over 72 weeks. Both groups lost meaningful weight. Tirzepatide simply lost more on average.
For a 200-pound starting weight, that translates roughly to 40 pounds lost on semaglutide at the strongest outcomes vs. about 45 pounds on tirzepatide. Not a 2x difference. But not nothing either.
Six Factors That Push the Decision One Way or the Other
Here’s where the real clinical thinking lives. When a doctor sits down with your labs and your goals, these are the factors that move the recommendation.
1. How Much Weight You Need to Lose
If you’re aiming for 10 to 15 percent of your body weight (a reasonable target for someone with mild metabolic resistance), both drugs can get you there. Semaglutide is plenty.
If you’re aiming for 20 percent or more, tirzepatide has the edge. The gap between the two medications widens at higher weight loss targets, and the dual mechanism becomes more useful when the body is fighting harder to hold onto fat.
2. Your Insulin Resistance and HOMA-IR
This is the factor most patients don’t know to ask about. HOMA-IR is a calculated measure of insulin resistance, derived from your fasting glucose and fasting insulin. The higher the number, the more insulin your pancreas has to pump out to keep your blood sugar in check, and the more your body is set up to store fat instead of burn it.
When HOMA-IR is significantly elevated, the GIP component of tirzepatide tends to matter more. GIP is involved in insulin sensitivity in a way GLP-1 isn’t, so patients with stubborn insulin resistance often respond better to the dual mechanism. Patients with normal or mildly elevated HOMA-IR can do well on either.
If you’ve never had your HOMA-IR measured, you’ve never had this conversation with the right amount of information. It’s one of the first things a real metabolic workup includes.
3. Whether You’ve Already Tried One of Them
If semaglutide is working for you, don’t switch. Switching medications mid-progress for marginal gains is rarely worth the disruption to your dosing curve, your side-effect adaptation, and your follow-up labs.
If you’ve plateaued on the maximum semaglutide dose for several months and your weight has truly stalled, that’s a different conversation. A switch to tirzepatide is often the right move at that point, especially if your HOMA-IR is still elevated.
4. Your Tolerance for Side Effects
Both medications cause gastrointestinal side effects: nausea, occasional vomiting, constipation, and sometimes diarrhea, particularly during dose escalation. The good news is that, on average, tirzepatide patients report fewer GI side effects at comparable effectiveness levels than semaglutide patients.
There’s a counterintuitive reason for that. Tirzepatide’s dual mechanism produces strong weight loss at lower relative doses, which means the GI burden stays manageable for many people. Semaglutide has to be pushed harder for the same outcome, and the higher the dose, the rougher the side effects.
If you have a particularly sensitive GI system or a history of gastroparesis, neither medication is automatic, and your prescriber should be paying close attention.
5. Cost, Coverage, and Access
This is where idealized clinical advice runs into reality. Insurance coverage for weight management peptides is patchy. Some plans cover Wegovy. Few cover Zepbound. Almost none cover both.
If your insurance covers Wegovy and not Zepbound, the math changes. Paying out of pocket for tirzepatide can run several hundred to over a thousand dollars per month depending on dose and pharmacy, and a real-world patient who can stay consistent on covered semaglutide often does better than a patient who starts and stops tirzepatide because of cost.
A note on compounded versions: the FDA declared the brand-name shortages resolved in early 2025, and compounding pharmacies were required to cease producing these peptides shortly after. If a clinic is still offering compounded semaglutide or tirzepatide, that’s a flag worth asking about.
6. What You’re Trying to Solve Long-Term
Weight loss is the headline outcome, but neither of these drugs is just a weight loss tool. They affect blood sugar, cardiovascular markers, sleep apnea (Zepbound is FDA-approved for moderate-to-severe OSA in adults with obesity), and inflammatory markers across the board.
If your real goal is reversing prediabetes or stabilizing A1c alongside weight management, the conversation broadens. Either medication can support that, but the choice should be made with the full lab picture in front of you, not just BMI.
When Semaglutide Is Probably the Better Fit
- You’re already on it and responding well.
- Your insurance covers Wegovy and not Zepbound, and out-of-pocket pricing is a real constraint.
- Your weight loss target is modest (under 15 percent of body weight).
- You tolerate it well and your bloodwork is moving in the right direction.
- You’re working with a clinician who is monitoring labs every few months and adjusting nutrition and activity alongside the medication.
When Tirzepatide Is Probably the Better Fit
- Your weight loss target is meaningful (15 percent of body weight or more).
- Your HOMA-IR is significantly elevated and insulin resistance is part of the picture.
- You’ve plateaued on a maximum dose of semaglutide.
- You’ve had bad GI side effects on semaglutide and want to try something with a typically gentler tolerability profile.
- You’re carrying weight-related comorbidities (sleep apnea, prediabetes, fatty liver) where the dual mechanism gives you broader metabolic coverage.
Where Most People Get This Wrong
The biggest mistake people make in choosing between these medications isn’t picking the wrong one. It’s picking either one without baseline labs.
Two patients can walk into the same telehealth pharmacy, both get prescribed the same dose of the same medication, and have wildly different outcomes. One loses 40 pounds. The other loses 12 and quits because of side effects. The difference is almost never the drug. It’s what the drug was being asked to do, in a body the prescriber never measured.
A real metabolic workup, including HOMA-IR, fasting insulin, A1c, full thyroid panel, lipid panel, and inflammatory markers, tells you which mechanism your body actually needs. It also gives you a baseline to track progress against, so when a result is or isn’t happening, you have data to interpret it.
Without that, you’re guessing. Sometimes the guess works. Often it doesn’t.
Talk to a Clinician Who Will Look at Your Labs
If you’re trying to decide between semaglutide and tirzepatide, the most useful next step isn’t another article. It’s a clinician who will run the labs, look at the data, and give you an actual recommendation grounded in your biology.
At The Adapt Lab in Solana Beach, Dr. Chad Larson leads a metabolic health clinic built around exactly that kind of work. Every patient starts with comprehensive metabolic testing, including HOMA-IR. From there, the recommendation, whether that’s semaglutide, tirzepatide, or another path entirely, comes from your data, not a default protocol.
If you’re ready to stop guessing, contact The Adapt Lab to schedule a consultation.
